Discontinued Operations	12 Months Ended
Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	9. Discontinued Operations: Divestiture of the Radiology Services Medical Group The Company divested its radiology services medical group in December 2020. The operating results of the radiology services medical group service line were reported as a component of discontinued operations, net of income taxes, in the Company’s Consolidated Statements of Income for the years ended December 31, 2020 and 2019. Loss from discontinued operations, net of income taxes, for the radiology services medical group for the years ended December 31, 2020 and December 31, 2019 was $63.8 million and $72.8 million, respectively. Net revenue for the radiology services medical group for the years ended December 31, 2020 and December 31, 2019 was $451.4 million and $489.4 million, respectively. Operating loss for the radiology services medical group for the year ended December 31, 2020 was $73.6 million, including a non-cash goodwill impairment charge of $47.0 million and a preliminary loss on sale of $36.4 million. Operating loss for the radiology services medical group for the year ended December 31, 2019 was $75.3 million, including a non-cash goodwill impairment charge of $117.9 million. During the year ended December 31, 2021, the Company recorded a net increase to the loss on sale of $4.0 million, primarily related to the adjustment of certain transaction related accounting. The net increase to the loss on sale is reflected as a component of discontinued operations, net of income taxes, in the Company’s Consolidated Statements of Income for the year ended December 31, 2021. Divestiture of the Anesthesiology Services Medical Group The Company divested its anesthesiology services medical group in May 2020. The operating results of the anesthesiology services medical group were reported as a component of discontinued operations, net of income taxes, in the Company’s Consolidated Statements of Income for the year ended December 31, 2020 and 2019. Loss from discontinued operations, net of income taxes, for the anesthesiology services medical group for the years ended December 31, 2020 and December 31, 2019 was $717.2 million and $1.12 billion, respectively. Net revenue for the anesthesiology services medical group for the years ended December 31, 2020 and December 31, 2019 was $379.4 million and $1.25 billion, respectively. Operating loss for the anesthesiology services medical group for the year ended December 31, 2020 was $716.3 million, including the loss on sale of $663.7 million. Operating loss for the anesthesiology services medical group for the year ended December 31, 2019 was $1.23 billion, including a non-cash goodwill impairment charge of $1.33 billion. During the year ended December 31, 2021, the Company recorded a net decrease to the loss on sale of $26.9 million, primarily related to an adjustment to the sales proceeds and book values of net assets sold resulting from a mutual agreement between the buyer and seller reached during the three months ended March 31, 2021 to treat a portion of the divestiture as an asset sale for tax purposes, the disposal of the single anesthesia practice that remained after the divestiture of the anesthesiology medical group in May 2020 and the completion of the valuation for the contingent economic consideration component of the transaction. The net decrease to the loss on sale is reflected as a component of discontinued operations, net of income taxes, in the Company’s Consolidated Statements of Income for the year ended December 31, 2021. The Company’s continuing operations financial statements for the year ended December 31, 2021 reflect the income tax effects associated with the asset sale change. This includes an increase in income tax receivable of $24 million, of which $9 million is related to loss carryback provisions enacted under the CARES Act, an increase in deferred tax assets of $17 million and a reduction to capital loss carryforwards and offsetting valuation allowance of $23 million. Divestiture of MedData In October 2019, the Company divested its management services organization, referred to as MedData. Loss from discontinued operations, net of tax, for MedData was $347.6 million for the year ended December 31, 2019, reflecting the loss on sale recorded during the year ended December 31, 2019. During the year ended December 31, 2020, the Company recorded a net incremental loss on the sale of MedData of $5.8 million, primarily for the finalization of certain transaction related expenses, a working capital true-up and incremental reserves related to indemnification matters, partially offset by the completion of its preliminary valuation for the contingent economic consideration.

Discontinued Operations

12 Months Ended

Dec. 31, 2021

Discontinued Operations and Disposal Groups [Abstract]

9. Discontinued Operations:

Divestiture of the Radiology Services Medical Group

The Company divested its radiology services medical group in December 2020. The operating results of the radiology services medical group service line were reported as a component of discontinued operations, net of income taxes, in the Company’s Consolidated Statements of Income for the years ended December 31, 2020 and 2019. Loss from discontinued operations, net of income taxes, for the radiology services medical group for the years ended December 31, 2020 and December 31, 2019 was $63.8 million and $72.8 million, respectively. Net revenue for the radiology services medical group for the years ended December 31, 2020 and December 31, 2019 was $451.4 million and $489.4 million, respectively. Operating loss for the radiology services medical group for the year ended December 31, 2020 was $73.6 million, including a non-cash goodwill impairment charge of $47.0 million and a preliminary loss on sale of $36.4 million. Operating loss for the radiology services medical group for the year ended December 31, 2019 was $75.3 million, including a non-cash goodwill impairment charge of $117.9 million.

During the year ended December 31, 2021, the Company recorded a net increase to the loss on sale of $4.0 million, primarily related to the adjustment of certain transaction related accounting. The net increase to the loss on sale is reflected as a component of discontinued operations, net of income taxes, in the Company’s Consolidated Statements of Income for the year ended December 31, 2021.

Divestiture of the Anesthesiology Services Medical Group

The Company divested its anesthesiology services medical group in May 2020. The operating results of the anesthesiology services medical group were reported as a component of discontinued operations, net of income taxes, in the Company’s Consolidated Statements of Income for the year ended December 31, 2020 and 2019. Loss from discontinued operations, net of income taxes, for the anesthesiology services medical group for the years ended December 31, 2020 and December 31, 2019 was $717.2 million and $1.12 billion, respectively. Net revenue for the anesthesiology services medical group for the years ended December 31, 2020 and December 31, 2019 was $379.4 million and $1.25 billion, respectively. Operating loss for the anesthesiology services medical group for the year ended December 31, 2020 was $716.3 million, including the loss on sale of $663.7 million. Operating loss for the anesthesiology services medical group for the year ended December 31, 2019 was $1.23 billion, including a non-cash goodwill impairment charge of $1.33 billion.

During the year ended December 31, 2021, the Company recorded a net decrease to the loss on sale of $26.9 million, primarily related to an adjustment to the sales proceeds and book values of net assets sold resulting from a mutual agreement between the buyer and seller reached during the three months ended March 31, 2021 to treat a portion of the divestiture as an asset sale for tax purposes, the disposal of the single anesthesia practice that remained after the divestiture of the anesthesiology medical group in May 2020 and the completion of the valuation for the contingent economic consideration component of the transaction. The net decrease to the loss on sale is reflected as a component of discontinued operations, net of income taxes, in the Company’s Consolidated Statements of Income for the year ended December 31, 2021.

The Company’s continuing operations financial statements for the year ended December 31, 2021 reflect the income tax effects associated with the asset sale change. This includes an increase in income tax receivable of $24 million, of which $9 million is related to loss carryback provisions enacted under the CARES Act, an increase in deferred tax assets of $17 million and a reduction to capital loss carryforwards and offsetting valuation allowance of $23 million.

Divestiture of MedData

In October 2019, the Company divested its management services organization, referred to as MedData. Loss from discontinued operations, net of tax, for MedData was $347.6 million for the year ended December 31, 2019, reflecting the loss on sale recorded during the year ended December 31, 2019.

During the year ended December 31, 2020, the Company recorded a net incremental loss on the sale of MedData of $5.8 million, primarily for the finalization of certain transaction related expenses, a working capital true-up and incremental reserves related to indemnification matters, partially offset by the completion of its preliminary valuation for the contingent economic consideration.